Read + Share
Smith TJ. Re: Shah et al.: Teprotumumab-related adverse events in thyroid eye disease: a
multicenter study (Ophthalmology. 2023 Oct 16:S0161-6420(23)00760-1). Ophthalmology 2024 Feb 10:S0161-6420(24)00002.
PMID: 38349297
|
 |
|
Smith TJ. Re: Shah et al.: Teprotumumab-related adverse events in thyroid eye disease: a
multicenter study (Ophthalmology. 2023 Oct 16:S0161-6420(23)00760-1). Ophthalmology 2024 Feb 10:S0161-6420(24)00002.
PMID: 38349297
|
|
|
|